A study assessing the switch ABP501 in naïve patients compared to a switch from Adalimumab originator
Latest Information Update: 10 Jul 2020
Price :
$35 *
At a glance
- Drugs Adalimumab (Primary)
- Indications Inflammatory bowel diseases
- Focus Therapeutic Use
- 10 Jul 2020 New trial record